DNA-Encoded Library (DEL) Selection Identifies a Distinct DDB1 Ligand Binding Site

Read full text
Authors: Shiva Krishna Reddy Guduru, John P. Caldwell, Katherine Marie Digianantonio, Sarah M. Prophet, Song Yang, Peter C. Gareiss, Christine Jones, Alicia Harbin, Brittany Driscoll, Md Fazlul Karim, Alexander Scott, Avani Patel
+21 more Amanda Chapman, Marci Crandall, Gabriella Miklóssy, Nicholas T. Barczak, Antonella P. Stroppa, John Corradi, Jordan J. Clark, Mee-Kyung Chung, Natalie RG. Reinhardt, William E. Butcher, Rashaun S. Wilson, Cory M. Stiff, Arman Fathizadeh, Lin Yuan, Gan Wang, Hanqing Dong, Brett R. Beno, Kurt Zimmermann (327735), David R. Langley, Angela M. Cacace, Miklós Békés
Cited by: 1
References: 25

Abstract

Heterobifunctional proteolysis targeting chimeras (PROTACs) are proven to degrade disease-causing proteins, and many PROTACs have already entered into clinical trials. The majority of these PROTACs recruit cereblon (CRBN) or von Hippel-Lindau (VHL) substrate receptors of cullin RING E3 ubiquitin ligases, but there remains a need for alternative E3 ligase ligands. In this study, we enable DDB1 as an E3 ligase adapter protein for PROTAC drug discovery, describe a DNA-encoded library (DEL) ligand discovery campaign, and report the identification of a novel DDB1 ligand. Structure-guided modifications allowed DDB1 ligands to be developed from the initial DEL hit with nanomolar potency. Biochemical assays, cellular target engagement, and X-ray crystallography analysis demonstrated binding of the ligand to a unique pocket within DDB1. This chemical series furthers our understanding of ligand binding pockets within DDB1 and expands the repertoire of small molecules that may be suitable for the incorporation into PROTACs.

Fields of Study & Subjects

Protein Degradation and Inhibitors HER2/EGFR in Cancer Research Histone Deacetylase Inhibitors Research

Publication details

Journal / source
ACS Medicinal Chemistry Letters
Publisher
American Chemical Society (ACS)
Volume
17
Issue
4
Pages
757–767
Publication date
27 March 2026
Language
EN